Divalproex Sodium Tablet, Delayed Release
Product Images NDC 60760-698

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 60760-698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

698-60 (Divalproex 60760 698 60)

This text provides information about a medication called Divalproex Sodium in tablet form. The tablets are delayed-release and contain 250mg of the active ingredient Valproic Acid. The prescription comes in a quantity of 60 tablets and carries the National Drug Code (NDC) number 60760-698-60. The medication is managed by Rising Health, LLC, located in Brunswick, NJ. It should be stored at room temperature between 15°C to 30°C (59°F-86°F) and used as directed.*

FDA Label Image

Figure 1 (Divalproex Fig1)

This text presents data from two studies comparing a placebo (PBO) with divalproex sodium delayed-release tablets (DVPX). The abbreviation "P80" is mentioned in reference to one of the studies. Additionally, there is a note indicating that statistical significance was reached with a p-value of less than 0.05.*

FDA Label Image

Figure 2 (Divalproex Fig2)

This is a chart showing the percentage of patients who experienced improvement, no change, or worsening of condition when treated with Divalproex Sodium Delayed-Release Tablets compared to placebo in CPS rats.*

FDA Label Image

Figure 3 (Divalproex Fig3)

This text shows a figure illustrating the percentage reduction in CPS rate, categorizing patients into high dose, low dose, improvement, no change, and worsening.*

FDA Label Image

Figure 4 (Divalproex Fig4)

This text provides information on the mean 4-week migraine rates in two studies comparing Placebo and Divalproex Sodium delayed-release tablets. It includes details on the mean dose of Divalproex Sodium delayed-release tablets used in the studies (1,087 mg/day) and the dosage range (500 or 1,000 mg/day) in Study 1 and Study 2.*

FDA Label Image

Chemical Structure (Divalproex Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.